Relationships between metabolic and non-metabolic susceptibility factors in benzene toxicity

Chemico-Biological Interactions

Volumn 184, Issue 1-2, 2010, Pages 222-228

  Ross, David ^a   Zhou, Hongfei ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Adhesion molecules; Benzene; Bone marrow endothelial cells; Metabolic susceptibility factors; NQO1; P53

Indexed keywords

BENZENE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; MUCONALDEHYDE; POLYPHENOL DERIVATIVE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BIOTRANSFORMATION; BONE MARROW TOXICITY; CELL SPECIFICITY; CHEMICAL STRUCTURE; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; METABOLIC ACTIVATION; METABOLIC REGULATION; MICROTUBULE; NONHUMAN; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PROTEIN CROSS LINKING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

BENZENE; BONE MARROW CELLS; CELL LINE, TRANSFORMED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE);

EID: 77950626841     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.11.017     Document Type: Article

References (110)

1. Aksoy M. Benzene hematotoxicity. Benzene carcinogenicity 1988, 59-112. CRC Press, Boca Raton. M. Aksoy (Ed.).
2. Aksoy M. Benzene carcinogenicity. Benzene carcinogenicity 1988, 113-151. CRC Press, Boca Raton. M. Aksoy (Ed.).
3. Snyder R., Longacre S.L., Witmer C.M., Kocsis J.J. Biochemical toxicology of benzene. Rev. Biochem. Tox. 1980, 3:123-154.
4. Kalf G.F. Recent advances in the metabolism and toxicity of benzene. Crit. Rev. Toxicol. 1987, 18:141-159.
5. Yardley-Jones A., Anderson D., Parke D.V. The toxicity of benzene and its metabolism and molecular pathology in human risk assessment. Br. J. Ind. Med. 1991, 48:437-444.
6. Snyder R., Hedli C.C. An overview of benzene metabolism. Environ. Health Perspect. 1996, 104(Suppl. 6):1165-1171.
7. Ross D. Metabolic basis of benzene toxicity. Eur. J. Haematol. 1996, 57(Suppl. 60):111-118.
8. Irons R.D., Greenlee W.F., Wierda D., Bus J.S. Relationship between benzene metabolism and toxicity: a proposed mechanism for the formation of reactive intermediates from polyphenol metabolites. Adv. Exp. Med. Biol. 1981, 136(Pt. A):229-243.
9. Cooper K.R., Snyder R. Benzene metabolism. Benzene Carcinogenicity 1988, 33-58. CRC Press, Boca Raton. M. Aksoy (Ed.).
10. Ross D. The role of metabolism and specific metabolites in benzene-induced toxicity: evidence and issues. J. Toxicol. Environ. Health A 2000, 61:357-372.
11. Valentine J.L., Lee S.S.T., Seaton M.J., Asgharian B., Farris G., Corton J.C., Gonzalez F.J., Medinsky M.A. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol. Appl. Pharmacol. 1996, 141:205-213.
12. Low L.K., Lambert C.E., Meeks J.R., Naro P.A., Mackerer C.R. Tissue specific metabolism of benzene in zymbal gland and other solid tumor target tissues in rats. J. Am. Coll. Toxicol. 1995, 14:40-60.
13. Tunek A., Platt K., Bentley P., Oesch F. Microsomal metabolism of benzene to species irreversibly binding to microsomal protein and effects of modifications of this metabolism. Mol. Pharmacol. 1978, 14:920-929.
14. Lindstrom A.B., Yeowell-O'Connell K., Waidyanatha S., McDonald T.A., Golding B.T., Rappaport S.M. Formation of hemoglobin and albumin adducts of benzene oxide in mouse, rat, and human blood. Chem. Res. Toxicol. 1998, 11:302-310.
15. 6]benzene. Cancer Res. 1994, 54:4907-4914.
16. Fuchs D., von Soo A., Hoppe-Seylers Z. Physiol. Chem. 1916, 98:11-13.
17. 14C-benzene. Biochem. J. 1953, 54:231-238.
18. Witz G., Latriano L., Goldstein B.D. Metabolism and toxicity of trans, trans-muconaldehyde, an open-ring microsomal metabolite of benzene. Environ. Health Perspect. 1989, 82:19-22.
19. Bleasdale C., Kennedy G., MacGregor J.O., Nieschalk J., Pearce K., Watson W.P., Golding B.T. Chemistry of muconaldehydes of possible relevance to the toxicology of benzene. Environ. Health Perspect. 1996, 104(Suppl. 6):1201-1209.
20. Rickert D.E., Baker T.S., Bus J.S., Barrow C.S., Irons R.D. Benzene disposition in the rat after exposure by inhalation. Toxicol. Appl. Pharmacol. 1979, 49:417-423.
21. Eastmond D.A., Smith M.T., Irons R.D. An interaction of benzene metabolites reproduces the myelotoxicity observed with benzene exposure. Toxicol. Appl. Pharmacol. 1987, 91:85-95.
22. Kolachana P., Subrahmanyam V.V., Meyer K.B., Zhang L., Smith M.T. Benzene and its phenolic metabolites produce oxidative DNA damage in HL-60 cells in vitro and in the bone marrow in-vivo. Cancer Res. 1993, 53:1023-1026.
23. Hiraku Y., Kawanishi S. Oxidative DNA damage and apoptosis induced by benzene metabolites. Cancer Res. 1996, 56:5172-5178.
24. Subrahmanyam V.V., Ross D., Eastmond D.A., Smith M.T. Potential role of free radicals in benzene-induced myelotoxicity and leukemia. Free Radic. Biol. Med. 1991, 11:495-515.
25. Sawahata T., Rickert D.E., Greenlee W.F. Metabolism of benzene and its metabolites in bone marrow. Toxicology of the Blood and Bone Marrow 1985, 141-148. Raven Press, New York. R.D. Irons (Ed.).
26. Sadler A., Subrahmanyam V.V., Ross D. Oxidation of catechol by horseradish peroxidase and human leukocyte peroxidase: reactions of o-benzoquinone and o-benzosemiquinone. Toxicol. Appl. Pharmacol. 1988, 93:62-71.
27. 6]benzene to rats. Carcinogenesis 1993, 14:1921-1925.
28. Pfeiffer E., Metzler M. Interaction of p-benzoquinone and p-biphenoquinone with microtubule proteins in vitro. Chem. Biol. Interact. 1996, 102:37-53.
29. 32P-postlabeling detection of benzene-DNA adducts in HL-60 cells, mouse bone marrow macrophages and human bone marrow. Carcinogenesis 1993, 14:2329-2334.
30. Monks T.J., Lau S.S. Toxicology of quinone-thioethers. Crit. Rev. Toxicol. 1992, 22:243-270.
31. Bratton S.B., Lau S.S., Monks T.J. Identification of quinol thioethers in bone marrow of hydroquinone/phenol-treated rats and mice and their potential role in benzene/mediated hematotoxicity. Chem. Res. Toxicol. 1997, 10:859-865.
32. Zhao Z., He X., Bi Y., Xia Y., Tao N., Li L., Ma Q. Induction of CYP4F3 by benzene metabolites in human white blood cells in vivo in human promyelocytic leukemic cell lines and ex vivo in human blood neutrophils. Drug Metab. Dispos. 2009, 37:282-291.
33. Przybyla-Zawislak B.D., Srivastava P.K., Vazquez-Matias J., Mohrenweiser H.W., Maxwell J.E., Hammock B.D., Bradbury J.A., Enayetallah A.E., Zeldin D.C., Grant D.F. Polymorphisms in human soluble epoxide hydrolase. Mol. Pharmacol. 2003, 64:482-490.
34. Twerdok L.E., Rembish S.J., Trush M.A. Induction of quinone reductase and glutathione in bone marrow cells by 1,2-dithiole-3-thione. Effect on hydroquinone-induced cytotoxicity. Toxicol. Appl. Pharmacol. 1992, 112:273-281.
35. London S.J., Lehman T.A., Taylor J.A. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997, 57:5001-5003.
36. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005, 45:51-88.
37. Traver R.D., Horikoshi T., Danenberg K.D., Stadlbauer T.H.W., Danenberg P.V., Ross D., Gibson N.W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992, 52:797-802.
38. Traver R.D., Siegel D., Beall H.D., Phillips R.M., Gibson N.W., Franklin W.A., Ross D. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br. J. Cancer 1997, 75:69-75.
39. Siegel D., McGuinness S.M., Winski S., Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999, 9:113-121.
40. Kelsey K.T., Wiencke J.K., Christiani D.C., Zuo Z., Spitz M.R., Xu X., Lee B.K., Schwartz B.S., Traver R.D., Ross D. Ethnic variation in the prevalence of a common NAD(P)H:quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br. J. Cancer 1997, 76:852-854.
41. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int. J. Clin. Pharmacol. Ther. 2000, 38:61-68.
42. Kiffmeyer W.R., Langer E., Davies S.M., Envall J., Robison L.L., Ross J.A. Genetic polymorphisms in the Hmong population: implications for cancer etiology and survival. Cancer 2004, 100:411-417.
43. Ross D., Siegel D. NQO1 functions and pharmacogenetics. Methods Enzymol. 2004, 382B:115-144.
44. Pan S.S., Forrest G.L., Akman S.A., Hu L.T. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. Cancer Res. 1995, 55:330-335.
45. Nebert D.W., Roe A.L., Vandale S.E., Bingham E., Oakley G.G. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet. Med. 2002, 4:62-70.
46. Jaiswal A.K, Burnett P., Adesnik M., McBride O.W. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry 1990, 29:1899-1906.
47. Winn L.M. Homologous recombination initiated by benzene metabolites: a potential role of oxidative stress. Toxicol. Sci. 2003, 72:143-149.
48. Naka K., Muraguchi T., Hoshii T., Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid. Redox. Signal. 2008, 10:1883-1894.
49. Ghaffari S. Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxid. Redox. Signal. 2008, 10:1923-1940.
50. Harrison K., Randoll F.W. An application of bone marrow cultures to toxicology and therapeutics. J. Exp. Phys. 1947, 34:141-152.
51. Long D.J., Gaikwad A., Multani A., Pathak S., Montgomery C.A., Gonzalez F.J., Jaiswal A.K. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res. 2002, 62:3030-3036.
52. Bauer A.K., Faiola B., Abernethy D.J., Marchan R., Pluta L.J., Wong V.A., Roberts K., Jaiswal A.K., Gonzalez F.J., Butterworth B.E., Borghoff S., Parkinson H., Everitt J., Recio L. Genetic susceptibility to benzene-induced toxicity: role of NADPH: quinone oxidoreductase-1. Cancer Res. 2003, 63:929-935.
53. Iskander K., Jaiswal A.K. Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem. Biol. Interact. 2005, 153-154:147-157.
54. 609C-->T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997, 57:2839-2842.
55. Recio L., Bauer A., Faiola B. Use of genetically modified mouse models to assess pathways of benzene-induced bone marrow cytotoxicity and genotoxicity. Chem. Biol. Interact. 2005, 153-154:159-164.
56. Smart R.C., Zannoni V.G. DT-diaphorase and peroxidase influence the covalent binding of the metabolites of phenol, the major metabolite of benzene. Mol. Pharmacol. 1984, 26:105-111.
57. Thomas D.J, Sadler A., Subrahmanyam V.V., Siegel D., Reasor M.J., Wierda D., Ross D. Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone: comparison of macrophages and fibroblastoid cells. Mol. Pharmacol. 1990, 37:255-262.
58. Zhu H., Li Y.B., Trush M.A. Differences in xenobiotic detoxifying activities between bone marrow stromal cells from mice and rats: Implications for benzene-induced hematotoxicity. J. Toxicol. Environ. Health 1995, 46:183-201.
59. Trush M.A., Twerdok L.E., Rembish S.J., Zhu H., Li Y.B. Analysis of target cell susceptibility as a basis for the development of a chemoprotective strategy against benzene-induced hematotoxicities. Environ. Health Perspect. 1996, 104(Suppl. 6):1227-1234.
60. Schattenberg D.G., Stillman W.S., Gruntmeir J.J., Helm K.M., Irons R.D., Ross D. Peroxidase activity in murine and human hematopoietic progenitor cells: potential relevance to benzene-induced toxicity. Mol. Pharmacol. 1994, 46:346-351.
61. Moran J.L., Siegel D., Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8150-8155.
62. Abernethy D.J., Kleymenova E.V., Rose J., Recio L., Faiola B. Human CD34+ hematopoietic progenitor cells are sensitive targets for toxicity induced by 1,4-benzoquinone. Toxicol. Sci. 2004, 79:82-89.
63. Wan J., Shi J., Guan J., Ye R., Gao X., Liu W., Hui L., Cao D., Jin X., Hu G., Xia Z. Relation of genetic polymorphism of NQO1 and GSTT1 with risks of chronic benzene poisoning. Zhonghua Lao. Dong. Wei Sheng Zhi. Ye. Bing. Za Zhi. 2002, 20:340-343.
64. Wan J., Shi J., Hui L., Wu D., Jin X., Zhao N., Huang W., Xia Z., Hu G. Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning. Environ. Health Perspect. 2002, 110:1213-1218.
65. Chen Y, Li G., Yin S., Xu J., Ji Z., Xiu X., Liu L., Ma D. Genetic polymorphisms involved in toxicant-metabolizing enzymes and the risk of chronic benzene poisoning in Chinese occupationally exposed populations. Xenobiotica 2007, 37:103-112.
66. Lan Q., Zhang L., Li G., Vermeulen R., Weinberg R.S., Dosemeci M., Rappaport S.M., Shen M., Alter B.P., Wu Y., Kopp W., Waidyanatha S., Rabkin C., Guo W., Chanock S., Hayes R.B., Linet M., Kim S., Yin S., Rothman N., Smith M.T. Hematotoxicity in workers exposed to low levels of benzene. Science 2004, 306:1774-1776.
67. Sun P., Qian J., Zhang Z.B., Wan J.X., Wu F., Jin X.P., Fan W.W., Lu D.R., Zhao N.Q., Christiani D.C., Xia Z.L. Polymorphisms in phase I and phase II metabolism genes and risk of chronic benzene poisoning in a Chinese occupational population. Carcinogenesis 2008, 29:2325-2329.
68. Dougherty D., Garte S., Barchowsky A., Zmuda J., Taioli E. NQO1, MPO, CYP2E1, GSTT1 and GSTM1 polymorphisms and biological effects of benzene exposure - a literature review. Toxicol. Lett. 2008, 182:7-17.
69. Kawasaki Y., Hirabayashi Y., Kaneko T., Kanno J., Kodama Y., Matsushima Y., Ogawa Y., Saitoh M., Sekita K., Uchida O., Umemura T., Yoon B.I., Inoue T. Benzene-induced hematopoietic neoplasms including myeloid leukemia in Trp53-deficient C57BL/6 and C3H/He mice. Toxicol. Sci. 2009, 110:293-306.
70. Yoon B.I., Li G.X., Kitada K., Kawasaki Y., Igarashi K., Kodama Y., Inoue T., Kobayashi K., Kanno J., Kim D.Y., Inoue T., Hirabayashi Y. Mechanisms of benzene-induced hematotoxicity and leukemogenicity: cDNA microarray analyses using mouse bone marrow tissue. Environ. Health Perspect. 2003, 111:1411-1420.
71. Boley S.E., Wong V.A., French J.E., Recio L. p53 heterozygosity alters the mRNA expression of p53 target genes in the bone marrow in response to inhaled benzene. Toxicol. Sci. 2002, 66:209-215.
72. Boley S.E., Anderson E.E., French J.E., Donehower L.A., Walker D.B., Recio L. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination. Cancer Res. 2000, 60:2831-2835.
73. Zhang L., Rothman N., Wang Y., Hayes R.B., Yin S.N., Li G.L., Smith M.T. Aneuploidy of chromosomes 7, 8 and 9 detected by fluorescence in-situ hybridization in workers exposed to benzene. Proc. Amer. Assoc. Cancer Res. 1995, 36:112.
74. Zhang L., Eastmond D.A., Smith M.T. The nature of chromosomal aberrations detected in humans exposed to benzene. Crit. Rev. Toxicol. 2002, 32:1-42.
75. Eastmond D.A., Mondrala S.T., Hasegawa L. Topoisomerase II inhibition by myeloperoxidase-activated hydroquinone: a potential mechanism underlying the genotoxic and carcinogenic effects of benzene. Chem. Biol. Interact. 2005, 153-154:207-216.
76. Lau A., Belanger C.L., Winn L.M. In utero and acute exposure to benzene: investigation of DNA double-strand breaks and DNA recombination in mice. Mutat. Res. 2009, 676:74-82.
77. Lan Q., Zhang L., Shen M., Jo W.J., Vermeulen R., Li G., Vulpe C., Lim S., Ren X., Rappaport S.M., Berndt S.I., Yeager M., Yuenger J., Hayes R.B., Linet M., Yin S., Chanock S., Smith M.T., Rothman N. Large-scale evaluation of candidate genes identifies associations between DNA repair and genomic maintenance and development of benzene hematotoxicity. Carcinogenesis 2009, 30:50-58.
78. Lan Q., Zhang L., Shen M., Smith M.T., Li G., Vermeulen R., Rappaport S.M., Forrest M.S., Hayes R.B., Linet M., Dosemeci M., Alter B.P., Weinberg R.S., Yin S., Yeager M., Welch R., Waidyanatha S., Kim S., Chanock S., Rothman N. Polymorphisms in cytokine and cellular adhesion molecule genes and susceptibility to hematotoxicity among workers exposed to benzene. Cancer Res. 2005, 65:9574-9581.
79. Lv L., Kerzic P., Lin G., Schnatter A.R., Bao L., Yang Y., Zou H., Fu H., Ye X., Gross S.A., Armstrong T.W., Irons R.D. The TNF-alpha 238A polymorphism is associated with susceptibility to persistent bone marrow dysplasia following chronic exposure to benzene. Leuk. Res. 2007, 31:1479-1485.
80. Hirabayashi Y. p53-dependent gene profiling for reactive oxygen species after benzene inhalation: special reference to genes associated with cell cycle regulation. Chem. Biol. Interact. 2005, 153-154:165-170.
81. Faiola B., Fuller E.S., Wong V.A., Recio L. Gene expression profile in bone marrow and hematopoietic stem cells in mice exposed to inhaled benzene. Mutat. Res. 2004, 549:195-212.
82. Sun P., Qiu Y., Zhang Z., Wan J., Wang T., Jin X., Lan Q., Rothman N., Xia Z.L. Association of genetic polymorphisms, mRNA expression of p53 and p21 with chronic benzene poisoning in a chinese occupational population. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1821-1828.
83. Lind C, Hochstein P., Ernster L. DT-Diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch. Biochem. Biophys. 1982, 216:178-185.
84. Thor H., Smith M.T., Hartzell P., Bellomo G., Jewell S.A., Orrenius S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implication of oxidative stress in intact cells. J. Biol. Chem. 1982, 257:12419-12425.
85. Faig M., Bianchet M.A., Talalay P., Chen S., Winski S., Ross D., Mario A.L. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:3177-3182.
86. Bianchet M.A., Faig M., Amzel L.M. Structure and mechanism of NADPH:quinone acceptor oxidoreductases (NQO). Methods Enzymol. 2004, 382:144-174.
87. Siegel D., Gustafson D.L., Dehn D.L., Han J.Y., Boonchoong P., Berliner L.J., Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol. Pharmacol. 2004, 65:1-10.
88. Wignall S.M., Gray N.S., Chang Y.T., Juarez L., Jacob R., Burlingame A., Schultz P.G., Heald R. Identification of a novel protein regulating microtubule stability through a chemical approach. Chem. Biol. 2004, 11:135-146.
89. Irons R.D., Neptun D.A. Effects of the principal hydroxy metabolites of benzene on microtubule polymerization. Arch. Toxicol. 1980, 45:297-305.
90. Asher G., Lotem J., Cohen B., Sachs L., Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1188-1193.
91. Gong X., Kole L., Iskander K., Jaiswal A.K. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res. 2007, 67:5380-5388.
92. Anwar A., Dehn D., Siegel D., Kepa J.K., Tang L.J., Pietenpol J.A., Ross D. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J. Biol. Chem. 2003, 278:10368-10373.
93. Siegel D., Ryder J., Ross D. NAD(P)H: quinone oxidoreductase 1 expression in human bone marrow endothelial cells. Toxicol. Lett. 2001, 125:93-98.
94. Schweitzer K.M., Vicart P., Delouis C., Paulin D., Drager A.M., Langenhuijsen M.M., Weksler B.B. Characterization of a newly established human bone marrow endothelial cell line: distinct adhesive properties for hematopoietic progenitors compared with human umbilical vein endothelial cells. Lab. Invest. 1997, 76:25-36.
95. Bironaite D., Siegel D., Moran J.L., Weksler B.B., Ross D. Stimulation of endothelial IL-8 (eIL-8) production and apoptosis by phenolic metabolites of benzene in HL-60 cells and human bone marrow endothelial cells. Chem. Biol. Interact. 2004, 149:37-49.
96. Zhou H., Kepa J.K., Siegel D., Shigenori M., Hiraki Y., Ross D. Benzene metabolite hydroquinone up-regulates chondromodulin-I and inhibits tube formation in human bone marrow endothelial cells. Mol. Pharmacol. 2009, 76:579-587.
97. Winski S.L., Faig M., Bianchet M.A., Siegel D., Swann E., Fung K., Duncan M.W., Moody C.J., Amzel L.M., Ross D. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. Biochemistry 2001, 40:15135-15142.
98. Zhou H, Dehn D., Kepa J.K., Siegel D., Ross D. Downregulation of the cellular adhesion molecule VCAM-1 in human bone marrow endothelial cells after inhibition of NQO1 activity. Proc. Am. Assoc. Cancer Res. 2007, 48:5371.
99. Dorshkind K. Regulation of hemopoiesis by bone marrow stromal cells and their products. Annu. Rev. Immunol. 1990, 8:111-137.
100. Eaves C.J., Cashman J.D., Kay R.J., Dougherty G.J., Otsuka T., Gaboury L.A., Hogge D.E., Lansdorp P.M., Eaves A.C., Humphries R.K. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood 1991, 78:110-117.
101. Yin T., Li L. The stem cell niches in bone. J. Clin. Invest. 2006, 116:1195-1201.
102. Zhang J., Li L. Stem cell niche: microenvironment and beyond. J. Biol. Chem. 2008, 283:9499-9503.
103. Ahn K.S., Sethi G., Jain A.K., Jaiswal A.K., Aggarwal B.B. Genetic deletion of NAD(P)H:quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, Ikappa Balpha kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. J. Biol. Chem. 2006, 281:19798-19808.
104. Pyatt D.W., Stillman W.S., Irons R.D. Hydroquinone, a reactive metabolite of benzene, inhibits NF-kappaB in primary human CD4+ T lymphocytes. Toxicol. Appl. Pharmacol. 1998, 149:178-184.
105. Pyatt D.W, Yang Y., Stillman W.S., Cano L.L., Irons R.D. Hydroquinone inhibits PMA-induced activation of NFkappaB in primary human CD19+ B lymphocytes. Cell Biol. Toxicol. 2000, 16:41-51.
106. Kerzic P.J., Pyatt D.W., Zheng J.H., Gross S.A., Le A., Irons R.D. Inhibition of NF-kappaB by hydroquinone sensitizes human bone marrow progenitor cells to TNF-alpha-induced apoptosis. Toxicology 2003, 187:127-137.
107. Zheng J.H., Pyatt D.W., Gross S.A., Le A.T., Kerzic P.J., Irons R.D. Hydroquinone modulates the GM-CSF signaling pathway in TF-1 cells. Leukemia 2004, 18:1296-1304.
108. Gross S.A., Zheng J.H., Le A.T., Kerzic P.J., Irons R.D. PU.1 phosphorylation correlates with hydroquinone-induced alterations in myeloid differentiation and cytokine-dependent clonogenic response in human CD34(+) hematopoietic progenitor cells. Cell Biol. Toxicol. 2006, 22:229-241.
109. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Tew K.D., Pincus M.R., Sardana M., Henderson C.J., Wolf C.R., Davis R.J., Ronai Z. Regulation of JNK signaling by GSTp. EMBO J. 1999, 18:1321-1334.
110. Ruscoe J.E., Rosario L.A., Wang T., Gate L., Arifoglu P., Wolf C.R., Henderson C.J., Ronai Z., Tew K.D. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J. Pharmacol. Exp. Ther. 2001, 298:339-345.